These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 19006840

  • 1. Aspects on the survival of patients with glioblastoma and the origin and histology of oligodendrogliomas.
    Linz U.
    Nat Rev Cancer; 2003 Jul; 3(7):doi:10.1038/nrc1121-c1. PubMed ID: 19006840
    [No Abstract] [Full Text] [Related]

  • 2. [Prognostic evaluation of histological criteria in central nervous system astrocytomas: 51 cases].
    Trabelsi S, Haouet S, Mekni A, Bouraoui S, Bellil K, Kchir N, Zitouna MM.
    Tunis Med; 2002 May; 80(5):274-7. PubMed ID: 12534032
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The changing management of low-grade astrocytomas and oligodendrogliomas.
    Agulnik M, Mason WP.
    Hematol Oncol Clin North Am; 2006 Dec; 20(6):1249-66. PubMed ID: 17113461
    [Abstract] [Full Text] [Related]

  • 5. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kölbl O, Flentje M.
    BMC Cancer; 2006 Oct 18; 6():247. PubMed ID: 17049083
    [Abstract] [Full Text] [Related]

  • 6. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
    Hagel C, Krog B, Laas R, Stavrou DK.
    J Exp Clin Cancer Res; 1999 Sep 18; 18(3):305-9. PubMed ID: 10606174
    [Abstract] [Full Text] [Related]

  • 7. [Results of multimodal treatment of patients with glial tumors of cerebral hemispheres].
    Cheremisin VM, Gaĭdar BV, Asaturian MA, Korobkova IM, Trufanov GE, Anosov NA.
    Vestn Rentgenol Radiol; 1995 Sep 18; (4):13-5. PubMed ID: 8571528
    [Abstract] [Full Text] [Related]

  • 8. Toward a glioblastoma vaccine: promise and potential pitfalls.
    Fine HA.
    J Clin Oncol; 2004 Nov 01; 22(21):4240-3. PubMed ID: 15452184
    [No Abstract] [Full Text] [Related]

  • 9. Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation.
    Wang KY, Vankov ER, Lin DDM.
    J Neurosurg Pediatr; 2018 Feb 01; 21(2):153-163. PubMed ID: 29192869
    [Abstract] [Full Text] [Related]

  • 10. [Combined treatment of glyal and metastatic tumors of the brain].
    Fadeev BP, Zhabina RM.
    Vestn Khir Im I I Grek; 2005 Feb 01; 164(1):80-2. PubMed ID: 15957817
    [Abstract] [Full Text] [Related]

  • 11. Oligodendrogliomas.
    Peterson K, Cairncross JG.
    Neurol Clin; 1995 Nov 01; 13(4):861-73. PubMed ID: 8584001
    [Abstract] [Full Text] [Related]

  • 12. [Conventional GBM vs GBMO: are these two diseases the same or not? -Update information].
    Ito T, Nakamura H, Tanaka S, Hasegawa T.
    No Shinkei Geka; 2014 Nov 01; 42(11):997-1008. PubMed ID: 25351795
    [No Abstract] [Full Text] [Related]

  • 13. [Association of 5-FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults].
    Bolla M, Vincent P, Benabid A, Mousseau M, de Rougemont J, Vrousos C, Kolodié H, Vincent F, Pasquier B.
    Bull Cancer Radiother; 1990 Nov 01; 77(1):53-9. PubMed ID: 8703542
    [Abstract] [Full Text] [Related]

  • 14. Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients.
    Deininger MH, Trautmann K, Meyermann R, Schluesener HJ.
    Anticancer Res; 2002 Nov 01; 22(3):1585-92. PubMed ID: 12168841
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V, Herold-Mende C.
    J Clin Oncol; 2004 Nov 01; 22(21):4272-81. PubMed ID: 15452186
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pseudoprogression in glioblastoma.
    Chamberlain MC.
    J Clin Oncol; 2008 Sep 10; 26(26):4359; author reply 4359-60. PubMed ID: 18779626
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.